CLRB - Cellectar Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.3100
-0.1500 (-6.10%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.4600
Open2.4400
Bid2.1000 x 1200
Ask2.3900 x 900
Day's Range2.2600 - 2.4601
52 Week Range1.2200 - 12.9000
Volume145,388
Avg. Volume187,788
Market Cap10.99M
Beta (3Y Monthly)1.13
PE Ratio (TTM)N/A
EPS (TTM)-5.2270
Earnings DateMay 9, 2019 - May 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.20
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    FDA Grants Exemption to Import Alert for Cellectar’s CLR 131 in Pediatric and Adolescent Patients

    Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted an exemption to the Import Alert placed on the Centre for Probe Development and Commercialization (CPDC) for the use of CLR 131 in connection with the company’s pediatric IND. This exemption will allow Cellectar to immediately begin enrolling patients in its Phase 1 pediatric study for the treatment of select relapsed or refractory solid tumors including neuroblastoma, lymphomas and malignant brain tumors.

  • GlobeNewswire25 days ago

    Cellectar Reports Financial Results for Year Ended December 31, 2018 and Provides a Corporate Update

    FLORHAM PARK, N.J., Feb. 26, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

  • GlobeNewswire26 days ago

    Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131

    Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced additional positive top-line results from its ongoing Phase 2 clinical study of CLR 131, the company’s lead product candidate. In the relapse refractory multiple myeloma cohort, CLR 131 achieved a 30% overall response rate in the first 10 evaluable patients.

  • GlobeNewswire2 months ago

    Cellectar Biosciences to Present at the Annual BIO CEO & Investor Conference

    FLORHAM PARK, N.J., Feb. 05, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

  • GlobeNewswire2 months ago

    Cellectar Biosciences to Present at NobleConXV, Noble Capital Markets’ Fifteenth Annual Investor Conference

    FLORHAM PARK, N.J., Jan. 23, 2019 -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

  • What Kind Of Shareholders Own Cellectar Biosciences, Inc. (NASDAQ:CLRB)?
    Simply Wall St.2 months ago

    What Kind Of Shareholders Own Cellectar Biosciences, Inc. (NASDAQ:CLRB)?

    If you want to know who really controls Cellectar Biosciences, Inc. (NASDAQ:CLRB), then you'll have to look at the makeup of its share registry. Insiders often own a large chunk Read More...

  • GlobeNewswire2 months ago

    Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma

    FLORHAM PARK, N.J., Jan. 07, 2019 -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

  • GlobeNewswire3 months ago

    Cellectar Biosciences to Present at the Biotech Showcase

    Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, announces that James Caruso, president and chief executive officer of Cellectar Biosciences, will present a company overview at the Biotech Showcase on Monday, January 7, 2019 at 10:00am Pacific Time.  The conference will be held at the Hilton San Francisco Union Square January 7-9, 2019. Cellectar's product candidates are built upon a patented delivery and retention platform that utilizes optimized phospholipid ether-drug conjugates (PDCs™) to target cancer cells. The PDC platform selectively delivers diverse oncologic payloads to cancerous cells and cancer stem cells, including hematologic cancers and solid tumors.

  • GlobeNewswire3 months ago

    Cellectar Granted Japanese Patent for CLR 131

    Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, announces that the Japan Patent Office has granted the patent titled “Phospholipid Analogs as Diapeutic Agents and Methods of Use Thereof” with application number 2016135920.  The patent provides composition of matter and use protection for the company’s proprietary phospholipid ether (PLE) analogs and specifically CLR 131 in breast, brain, leukemias and a variety of other cancers.

  • Analysts Take Action on Health Care Stocks
    GuruFocus.com4 months ago

    Analysts Take Action on Health Care Stocks

    The analyst established a price target of $174 per share, which represents 38.3% upside from the share price of $125.8 at market close on Tuesday. The share price has increased 46% over the 52 weeks of trading through Nov. 20. Warning! GuruFocus has detected 6 Warning Signs with BGNE.

  • GlobeNewswire4 months ago

    Cellectar Reports Third Quarter 2018 Financial Results and Provides Business Update

    Cellectar Biosciences, Inc. (CLRB) (“Cellectar” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today reported financial results for the three and nine months ended September 30, 2018 and provided a business update. Announced that the U.S. Food and Drug Administration has granted an exemption to the Import Alert for CLR 131 in all hematology indications, effective immediately.  The company continues to work with the appropriate division of the FDA to obtain an exemption for its pediatric program, evaluating CLR 131 in multiple childhood cancers with significant unmet medical need.

  • ACCESSWIRE6 months ago

    Today's Research Reports on Trending Tickers: Onconova Therapeutics and Cellectar Biosciences

    NEW YORK, NY / ACCESSWIRE / September 27, 2018 / U.S. markets fell sharply Wednesday after the Federal Reserve raised interest rates and indicated another increase would be coming in December. The Dow ...

  • Benzinga7 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! TAL Education Group (ADR) (NYSE: TAL ) stock was trading ...